<DOC>
	<DOCNO>NCT02019485</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence ( biological equivalence two formulation study medication ) new tapentadol Extended release ( ER ) 100 mg tamper-resistant formulation ( TRF ) tablet , current tapentadol ER 100 mg , prolonged-release formulation 2 ( PR2 ) tablet use healthy participant fast ( without food ) condition .</brief_summary>
	<brief_title>A Study Assess Bioequivalence New Tapentadol Extended-Release Tablet With Respect Tapentadol Extended Release Tablet Under Fasted Conditions Healthy Subjects</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , randomize ( study medication assign chance ) , 2-way crossover ( method use switch participant one treatment arm another clinical study ) , single-dose , single-center study . The study consist 3 phase : screening phase , treatment phase , end-of-study withdrawal assessment phase . In treatment phase , participant receive single dose new tapentadol ER 100-mg TRF tablet ( Treatment A ) current tapentadol ER 100-mg PR2 ( Treatment B ) fast condition 2 treatment sequence ( AB BA ) . Administration study medication separate washout period ( treatment ) 7 to14 day . Approximately 64 participant enrol study . Safety evaluate assessment adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination . The duration participation study individual participant approximately 5.5 week .</detailed_description>
	<criteria>Agrees protocoldefined use effective contraception Body mass index ( BMI ) 20 28 kilogram per square meter , inclusive , body weight less 50 kg ( BMI calculate weight [ kilogram ] divide square height [ meter ] ) Habitually smoke 10 cigarette , 2 cigar , 2 pipe tobacco per day least 6 month first study medication administration History seizure disorder epilepsy mild severe traumatic brain injury Men hemoglobin concentration 12.5 g/dL woman hemoglobin concentration 11.5 g/dL Positive test drug abuse , cannabinoids , alcohol , opiates , cocaine , amphetamine , benzodiazepine , barbiturate screen Day 1 treatment period Positive test human immunodeficiency virus antibody , hepatitis B surface antigen , hepatitis C antibodies History gastrointestinal disease affect absorption , gastric surgery history current significant medical illness</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Tapentadol</keyword>
	<keyword>Tapentadol extended-release tamper-resistant formulation</keyword>
	<keyword>Tapentadol extended-release prolonged-release formulation</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Fasted Conditions</keyword>
</DOC>